Cargando…

Resectable IIIA-N2 Non-Small-Cell Lung Cancer (NSCLC): In Search for the Proper Treatment

Locally advanced non-small cell lung cancer accounts for one third of non-small cell lung cancer (NSCLC) at the time of initial diagnosis and presents with a wide range of clinical and pathological heterogeneity. To date, the combined multimodality approach involving both local and systemic control...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brascia, Debora, De Iaco, Giulia, Schiavone, Marcella, Panza, Teodora, Signore, Francesca, Geronimo, Alessandro, Sampietro, Doroty, Montrone, Michele, Galetta, Domenico, Marulli, Giuseppe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7465235/ https://www.ncbi.nlm.nih.gov/pubmed/32722386 http://dx.doi.org/10.3390/cancers12082050

Ejemplares similares

Lymph Nodes Involvement and Lymphadenectomy in Thymic Tumors: Tentative Answers for Unsolved Questions
por: Brascia, Debora, et al.
Publicado: (2021)

How to identify intersegmental planes in performing sublobar anatomical resections
por: Nex, Giulia, et al.
Publicado: (2020)

Case report: Successful multimodal assessment and management of chemothorax
por: Panza, Teodora, et al.
Publicado: (2022)

Case Report: Inferior Bilobectomy for Lung Cancer to Allow Weaning From Veno-Venous Extracorporeal Membrane Oxygenation
por: Signore, Francesca, et al.
Publicado: (2021)

Not only acute respiratory failure: COVID-19 and the post-intubation/tracheostomy upper airways lesions(†)
por: Brascia, Debora, et al.
Publicado: (2023)

Multidisciplinary Approach in the Treatment of Descending Necrotizing Mediastinitis: Twenty-Year Single-Center Experience
por: De Palma, Angela, et al.
Publicado: (2022)

Pulmonary Sclerosing Pneumocytoma: A Pre and Intraoperative Diagnostic Challenge. Report of Two Cases and Review of the Literature
por: Trabucco, Senia Maria Rosaria, et al.
Publicado: (2021)

Controversial role of mast cells in NSCLC tumor progression and angiogenesis
por: Longo, Vito, et al.
Publicado: (2022)

Surgical Principles in the Management of Lung Neuroendocrine Tumors: Open Questions and Controversial Technical Issues
por: Brascia, Debora, et al.
Publicado: (2022)

Biomarkers for efficacy of adjuvant chemotherapy following complete resection in NSCLC stages I–IIIA
por: Wallerek, Sandra, et al.
Publicado: (2015)

Catamenial pneumothorax: Not only VATS diagnosis
por: Quercia, Rosatea, et al.
Publicado: (2023)

Selection of proper candidates with resected pathological stage IIIA-N2 non-small cell lung cancer for postoperative radiotherapy
por: Hui, Zhouguang, et al.
Publicado: (2015)

A comparison of FLT to FDG PET/CT in the early assessment of chemotherapy response in stages IB–IIIA resectable NSCLC
por: Crandall, John P., et al.
Publicado: (2017)

Esophageal Stricture Caused by ALK-Positive NSCLC Esophageal Metastasis Resolved After a Few Days of Lorlatinib Therapy Without Stent Placement
por: Longo, Vito, et al.
Publicado: (2020)

Cost-effectiveness analysis of adjuvant therapy with atezolizumab in Chinese patients with stage IB-IIIA resectable NSCLC after adjuvant chemotherapy
por: Chen, Ping, et al.
Publicado: (2022)

Systemic Therapy for Oligoprogression in Patients with Metastatic NSCLC Harboring Activating EGFR Mutations
por: Rossi, Antonio, et al.
Publicado: (2022)

A CT-based transfer learning approach to predict NSCLC recurrence: The added-value of peritumoral region
por: Bove, Samantha, et al.
Publicado: (2023)

Effects of postoperative radiotherapy on cardiovascular-pulmonary disease mortality in patients with stage IIIA-N2 resected NSCLC: analysis of the SEER database
por: Wang, Xia, et al.
Publicado: (2021)

Deconstructing ADAURA. It is Not Yet Time to Forgo Platinum-based Adjuvant Chemotherapy in Resected Early Stage (IB-IIIA) EGFR-mutant NSCLC
por: Brazel, Danielle, et al.
Publicado: (2022)

A Phase 1 Study of Concurrent Neoadjuvant Pembrolizumab Plus Chemoradiation Followed by Consolidation Pembrolizumab in Patients With Resectable Stage IIIA NSCLC
por: Lemmon, Christopher A., et al.
Publicado: (2022)

Lymph node volume predicts survival but not nodal clearance in Stage IIIA-IIIB NSCLC
por: Agrawal, Vishesh, et al.
Publicado: (2017)

Clinical significance of DNA damage response mutations in stage I and stage IIIa NSCLC
por: Zhang, Haoran, et al.
Publicado: (2023)

Safety evaluation of immune checkpoint inhibitors combined with chemotherapy for the treatment of small cell lung cancer: A meta‐analysis of randomized controlled trials
por: Longo, Vito, et al.
Publicado: (2023)

Favourable outcome of coronavirus disease 2019 in a patient with anaplastic lymphoma kinase-positive non-small-cell lung cancer receiving alectinib
por: Montrone, Michele, et al.
Publicado: (2020)

Robotic-assisted thoracoscopic surgery for clinically stage IIIA (c-N2) NSCLC—is it justified?
por: Weder, Walter, et al.
Publicado: (2021)

Adjuvant osimertinib treatment in patients with early stage NSCLC (IB-IIIA): pathological pathway adaptations
por: Marchetti, Antonio, et al.
Publicado: (2022)

Preliminary Results of Robotic Lobectomy in Stage IIIA-N2 NSCLC after Induction Treatment: A Case Control Study
por: Casiraghi, Monica, et al.
Publicado: (2021)

Robotic-assisted resection of intralobar and extralobar pulmonary sequestration
por: Galetta, Domenico, et al.
Publicado: (2022)

Deconstructing ADAURA: It is Time to Forgo Adjuvant Platinum-Based Chemotherapy in Resected IB-IIIA EGFR+ NSCLC (Except with RB Alterations?) When Adopting Adjuvant Osimertinib
por: Zhang, Shannon S, et al.
Publicado: (2022)

Case Report: Adjuvant Crizotinib Therapy Exerted Favorable Survival Benefit in a Resectable Stage IIIA NSCLC Patient With Novel LDLR–ROS1 Fusion
por: Chen, An-guo, et al.
Publicado: (2022)

Cancer Associated Fibroblasts in Stage I-IIIA NSCLC: Prognostic Impact and Their Correlations with Tumor Molecular Markers
por: Kilvaer, Thomas K., et al.
Publicado: (2015)

Trimodally treatment for stage IIIa NSCLC patients increases survival while not effecting surgical mortality or complexity
por: Dan, Aravot, et al.
Publicado: (2019)

Monitoring with circulating tumor cells in the perioperative setting of patients with surgically treated stages I–IIIA NSCLC
por: Garitaonaindia, Yago, et al.
Publicado: (2023)

The Valuable Prognostic Impact of Regional Lymph Node Removed on Outcomes for IIIA N0 NSCLC Patients
por: Wang, Yukun, et al.
Publicado: (2023)

Neoadjuvant anti-programmed Death-1 immunotherapy by Pembrolizumab in resectable nodal positive stage II/IIIa non-small-cell lung cancer (NSCLC): the NEOMUN trial
por: Eichhorn, Florian, et al.
Publicado: (2019)

Correction to: Trimodally treatment for stage IIIa NSCLC patients increases survival while not effecting surgical mortality or complexity
por: Aravot, Dan, et al.
Publicado: (2019)

Neoadjuvant chemoimmunotherapy as a potential therapeutic option in NSCLC UICC stage IIIA with multilevel N2 disease
por: Menghesha, Hruy, et al.
Publicado: (2022)

Prognostic factors for survival in extensive‐stage small cell lung cancer: An Italian real‐world retrospective analysis of 244 patients treated over the last decade
por: Longo, Vito, et al.
Publicado: (2022)

Multicenter randomized study on the comparison between electronic and traditional chest drainage systems
por: Marulli, Giuseppe, et al.
Publicado: (2019)

The impact of order with radiation therapy in stage IIIA pathologic N2 NSCLC patients: a population-based study
por: Duan, Hongxia, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_5nph43m8dc0r3h06amkn5d4le5